First drug to treat postpartum depression approved in U.S., but questions linger

The U.S. Food and Drug Administration approved Zulresso -- also known as brexanolone -- an intravenous drug that must be administered in a clinical setting over 60 consecutive hours.

Postpartum depression can start during pregnancy or at any time up to a year after the baby is born. Symptoms include feelings of sadness, guilt, anger or worthlessness. In serious cases, some women experience suicidal thoughts. “A lot of patients … spoke about how it made a difference in their lives, but given the really small amount of patients in those trials, we didn’t really get to see the other side of the coin,” shetold CTV News. “We really don’t know the profiles of women…for whom the drug did not work.”

“The side effects are certainly things that need to be monitored and observed,” Meltzer-Brody acknowledged.

There'd be less depression if people would get off their ass and exercise!

would you take a drug where 'questions linger'

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Ottawa signs funding deal to help relieve housing crisis at Cat Lake First NationFederal investment totals $12.8-million to support the remote Northern Ontario community, where the crisis has begun to affect residents’ health How about reinstating audits of funding? Make band leaders accountable for spending or better yet end the funding altogether & just build new homes, infrastructure etc instead of free money. Get reserve to a modern level & then reduce money after that to only maintenance level If that's the air terminal what can the homes look like? Move
Source: globeandmail - 🏆 5. / 92 Read more »